Pfizer will end the global commercialisation of its haemophilia gene therapy Beqvez (fidanacogene elaparvovec) amid low ...

According to multiple media reports on Thursday, Pfizer Inc. (NYSE:PFE) has terminated the global development and ...

One of the largest pharmaceutical companies in North Carolina is discontinuing a treatment produced in the state.

Pfizer’s decision to halt further marketing of Beqvez is further sign of the sparse patient interest in gene therapies for the bleeding condition.

Guardant Health (NYSE:GH) reported fourth-quarter adjusted EPS loss of 62 cents, compared to a loss of 64 cents a year ago, ...